Nakashima Kei, Saruwatari Koichi, Sato Ryo, Imamura Kosuke, Kajihara Ikko, Fukushima Satoshi, Saito Tetsuo, Ishizuka Shiho, Tamanoi Daisuke, Jodai Takayuki, Hamada Shohei, Tomita Yusuke, Saeki Sho, Ichiyasu Hidenori, Oya Natsuo, Ihn Hironobu, Sakagami Takuro
Department of Respiratory Medicine, Kumamoto University Hospital, Japan.
Department of Dermatology and Plastic Surgery, Kumamoto University Hospital, Japan.
Intern Med. 2020 May 1;59(9):1199-1202. doi: 10.2169/internalmedicine.3937-19. Epub 2020 Feb 12.
Radiation recall dermatitis (RRD) is an inflammatory reaction that occurs at previously irradiated skin regions after drug administration. We herein report a patient with non-small-cell lung cancer treated previously with thoracic radiotherapy who developed severe RRD induced by atezolizumab [anti-programmed death 1 ligand 1 (PD-L1) antibody]. Immunohistochemistry of the skin biopsy showed dermatitis with infiltration of CD8+ lymphocytes, suggesting that atezolizumab might provoke an immune-related inflammatory reaction at previously irradiated skin regions. When administering anti-PD-L1 antibody to patients who have undergone radiotherapy previously, physicians should carefully monitor the irradiated skin for the potential occurrence of RRD.
放射性回忆性皮炎(RRD)是一种在给药后于先前接受过放射治疗的皮肤区域发生的炎症反应。我们在此报告一名曾接受胸部放疗的非小细胞肺癌患者,其发生了由阿替利珠单抗[抗程序性死亡1配体1(PD-L1)抗体]诱发的严重RRD。皮肤活检的免疫组织化学显示皮炎伴CD8 +淋巴细胞浸润,提示阿替利珠单抗可能在先前接受过放射治疗的皮肤区域引发免疫相关的炎症反应。当对先前接受过放疗的患者使用抗PD-L1抗体时,医生应仔细监测放疗过的皮肤,以防RRD的潜在发生。